Rogier Christiaan Buijsman

Title: Rogier Christiaan Buijsman: Innovator in Cancer Treatment

Introduction

Rogier Christiaan Buijsman is a notable inventor based in Berghem, Netherlands. He has made significant contributions to the field of cancer treatment through his innovative research and patented methodologies. With a total of 2 patents, Buijsman is dedicated to improving therapeutic options for patients.

Latest Patents

Buijsman's latest patents focus on prognostic biomarkers for TTK inhibitor chemotherapy. One of his methods involves identifying tumors that are susceptible to treatment with a TTK inhibitor. This process includes providing a sample of a tumor and determining the presence of a mutated CTNNB1 gene in the sample. The mutation is specifically located in exon 3 of the CTNNB1 gene, and its presence indicates that the tumor is likely to respond to TTK inhibitor treatment. Alternatively, the method can involve determining the presence of a mutated CTNNB1 protein or assessing altered expression of a CTNNB1 regulated gene, both of which also indicate susceptibility to treatment.

Career Highlights

Buijsman is associated with the Netherlands Translational Research Center B.V., where he continues to advance his research in cancer therapies. His work is characterized by a commitment to translating scientific discoveries into practical applications that can benefit patients.

Collaborations

He collaborates with esteemed colleagues such as Jeroen De Roos and Joost Cornelis Marinus Uitdehaag, contributing to a dynamic research environment focused on innovative cancer treatments.

Conclusion

Rogier Christiaan Buijsman is a pioneering inventor whose work in cancer treatment through TTK inhibitors showcases his dedication to improving patient outcomes. His innovative methodologies and collaborations highlight the importance of research in the fight against cancer.